To explore the diffusion capacities between the anterior and vitreous chambers in a novel ex vivo pig eye model using a mix of stable isotope-labeled acylcarnitines representing metabolites with different physical and chemical properties, and analysis using mass spectrometry (MS).
Methods:
Enucleated pig eyes were injected in the anterior or vitreous chamber of the eye with a stable isotope-labeled acylcarnitine mix (free carnitine, C2, C3, C4, C8, C12, and C16—having an increasing size and hydrophobicity in that order). Samples were collected from each chamber at 3, 6, and 24 h postincubation for analysis using MS.
Results:
After injection into the anterior chamber, the concentration of all acylcarnitines increased in the vitreous chamber over the observation period. After injection in the vitreous chamber, the acylcarnitines diffused to the anterior chamber with the highest concentration observed at 3 h postinjection, followed by a decrease in concentration possibly due to an elimination from the anterior chamber despite continued diffusion from the vitreous chamber. C16, the most hydrophobic and longest chain molecule, showed slower diffusion in both experimental settings.
Conclusion:
We hereby show a distinct diffusion pattern of molecules with different molecular size and hydrophobicity within and between the anterior and vitreous chamber. This model can be useful for optimizing choices and design of therapeutic molecules with higher retaining or depot properties into the two chambers of the eye for future intravitreal, intracameral, and topical treatment purposes.
Get full access to this article
View all access options for this article.
References
1.
SteinmetzJD, BourneRRA, BriantPS, et al.Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: The right to sight: An analysis for the Global Burden of Disease Study. Lancet Global Health, 2021; 9(2):e144–e160; doi: 10.1016/s2214-109x(20)30489-7
WongWL, SuX, LiX, et al.Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Global Health, 2014; 2(2):e106–e116; doi: 10.1016/s2214-109x(13)70145-1
SabanayagamC, BanuR, CheeML, et al.Incidence and progression of diabetic retinopathy: A systematic review. Lancet Diabetes Endocrinol, 2019; 7(2):140–149; doi: 10.1016/s2213-8587(18)30128-1
6.
LeasherJL, BourneRRA, FlaxmanSR, et al.Global estimates on the number of people blind or visually impaired by diabetic retinopathy: A meta-analysis from 1990 to 2010. Diabetes Care, 2016; 39(9):1643–1649; doi: 10.2337/dc15-2171
7.
LeeR, WongTY, SabanayagamC.Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis, 2015; 2(1); doi: 10.1186/s40662-015-0026-2
8.
SawadaO, OhjiM.Retinal vein occlusion. In: Developments in Ophthalmology. (NgyuenQD, RodriguesEB, FarahME, et al., eds.) S. Karger AG: Basel, Switzerland; 2015; pp. 147–153.
HolzFG, Schmitz-ValckenbergS, FleckensteinM. Recent developments in the treatment of age-related macular degeneration. J Clin Invest, 2014; 124(4):1430–1438; doi: 10.1172/jci71029
11.
El RamiH, BarhamR, SunJK, et al.Evidence-based treatment of diabetic retinopathy. Semin Ophthalmol, 2017; 32(1):67–74; doi: 10.1080/08820538.2016.1228397
12.
HengLZ, ComynO, PetoT, et al.Diabetic retinopathy: Pathogenesis, clinical grading, management and future developments. Diabet Med, 2013; 30(6):640–650; doi: 10.1111/dme.12089
13.
SunK, JampolM. The Diabetic Retinopathy Clinical Research Network (DRCR.net) and its contributions to the treatment of diabetic retinopathy. Ophthalmic Res, 2019; 62(4):225–230; doi: 10.1159/000502779
14.
WuL, Martínez-CastellanosMA, Quiroz-MercadoH, et al.Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the pan-american collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol, 2007; 246(1):81–87; doi: 10.1007/s00417-007-0660-z
15.
Varela-FernándezR, Díaz-ToméV, Luaces-RodríguezA, et al.Drug delivery to the posterior segment of the eye: Biopharmaceutic and pharmacokinetic considerations. Pharmaceutics, 2020; 12(3):269; doi: 10.3390/pharmaceutics12030269
16.
Ghasemi FalavarjaniK, NguyenQD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature. Eye, 2013; 27(7):787–794; doi: 10.1038/eye.2013.107
CheungCSY, WongAWT, LuiA, et al.Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology, 2012; 119(8):1609–1614; doi: 10.1016/j.ophtha.2012.02.014
19.
KrohneTU, EterN, HolzFG, et al.Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol, 2008; 146(4):508–512; doi: 10.1016/j.ajo.2008.05.036
20.
BakriSJ, SnyderMR, ReidJM, et al.Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology, 2007; 114(5):855–859; doi: 10.1016/j.ophtha.2007.01.017
21.
GoelM.Aqueous humor dynamics: A review. Open Ophthalmol J, 2010; 4(1):52–59; doi: 10.2174/1874364101004010052
22.
CarreonT, Van Der MerweE, FellmanRL, et al.Aqueous outflow—A continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res, 2017; 57:108–133; doi: 10.1016/j.preteyeres.2016.12.004
MauriceDM.Flow of water between aqueous and vitreous compartments in the rabbit eye. Am J Physiol, 1987; 252(1):F104–F108; doi: 10.1152/ajprenal.1987.252.1.f104
26.
LoftssonT.Topical drug delivery to the retina: Obstacles and routes to success. Expert Opin Drug Deliv, 2022; 19(1):9–21; doi: 10.1080/17425247.2022.2017878
27.
Del AmoEM, RimpeläA-K, HeikkinenE, et al.Pharmacokinetic aspects of retinal drug delivery. Prog Retin Eye Res, 2017; 57:134–185; doi: 10.1016/j.preteyeres.2016.12.001
28.
FogliS, Del ReM, RofiE, et al.Clinical pharmacology of intravitreal anti-VEGF drugs. Eye, 2018; 32(6):1010–1020; doi: 10.1038/s41433-018-0021-7
29.
MoghimipourE, SalimiA, KaramiM, et al.Preparation and characterization of dexamethasone microemulsion based on pseudoternary phase diagram. Jundishapur J Nat Pharm Prod, 2013; 8(3):105–112; doi: 10.17795/jjnpp-9373
30.
PeetersL, SandersNN, BraeckmansK, et al.Vitreous: A barrier to nonviral ocular gene therapy. Invest Opthalmol Visual Sci, 2005; 46(10):3553; doi: 10.1167/iovs.05-0165
31.
XuQ, BoylanNJ, SukJS, et al.Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J Controlled Release, 2013; 167(1):76–84; doi: 10.1016/j.jconrel.2013.01.018
32.
RimpeläA-K, ReunanenS, HagströmM, et al.Binding of small molecule drugs to porcine vitreous humor. Mol Pharmaceutics, 2018; 15(6):2174–2179; doi: 10.1021/acs.molpharmaceut.8b00038
33.
AgrahariV, MandalA, AgrahariV, et al.A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res, 2016; 6(6):735–754; doi: 10.1007/s13346-016-0339-2
34.
SchwabC, PaarM, FenglerVH, et al.Gender differences in albumin and ascorbic acid in the vitreous antioxidant system. Free Radic Biol Med, 2020; 146:257–263; doi: 10.1016/j.freeradbiomed.2019.11.008
35.
FuchsH, IgneyF. Binding to ocular albumin as a half-life extension principle for intravitreally injected drugs: Evidence from mechanistic rat and rabbit studies. J Ocul Pharmacol Ther, 2017; 33(2):115–122; doi: 10.1089/jop.2016.0083
36.
CampbellM, HumphriesP.The blood-retina barrier. In: Advances in Experimental Medicine and Biology. (ChengCY. ed.) Springer: New York, NY, USA; 2013; pp. 70–84.
37.
TörnquistP, AlmA, BillA. Permeability of ocular vessels and transport across the blood-retinal-barrier. Eye, 1990; 4(2):303–309; doi: 10.1038/eye.1990.41
38.
HosoyaK-I, TachikawaM. Inner blood-retinal barrier transporters: Role of retinal drug delivery. Pharm Res, 2009; 26(9):2055–2065; doi: 10.1007/s11095-009-9930-2
39.
Cunha-VazJ.Blood-retinal barrier. In: Encyclopedia of the Eye. (DarttDA. ed.) Elsevier: Coimbra, Portugal; 2010; pp. 209–215.
40.
LiuL, LiuX.Roles of drug transporters in blood-retinal barrier. In: Drug Transporters in Drug Disposition, Effects and Toxicity. (LiuX, PanG. eds.) Advances in Experimental Medicine and Biology. Springer: Singapore, Singapore; 2019; pp. 467–504; doi: 10.1007/978-981-13-7647-4_10
41.
StamperRL, LiebermanMF, DrakeMV. Aqueous humor formation. In: Becker-Shaffer's Diagnosis and Therapy of the Glaucomas. Elsevier: California, CA, USA; 2009; pp. 8–24.
42.
BeerPM, BakriSJ, SinghRJ, et al.Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology, 2003; 110(4):681–686; doi: 10.1016/s0161-6420(02)01969-3
43.
KrohneTU, LiuZ, HolzFG, et al.Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol, 2012; 154(4):682–686.e2; doi: 10.1016/j.ajo.2012.03.047
44.
KimH, CsakyKG, ChanC-C, et al.The pharmacokinetics of rituximab following an intravitreal injection. Exp Eye Res, 2006; 82(5):760–766; doi: 10.1016/j.exer.2005.09.018
45.
FreddoTF.A contemporary concept of the blood–aqueous barrier. Prog Retin Eye Res, 2013; 32:181–195; doi: 10.1016/j.preteyeres.2012.10.004
Microsoft Corporation. Microsoft Excel [Internet]. 2018. Available from: https://office.microsoft.com/excel [Last accessed: May 8, 2023].
48.
HimawanE, EkströmP, BuzgoM, et al.Drug delivery to retinal photoreceptors. Drug Discov Today, 2019; 24(8):1637–1643; doi: 10.1016/j.drudis.2019.03.004
49.
KimHM, WooSJ. Ocular drug delivery to the retina: Current innovations and future perspectives. Pharmaceutics, 2021; 13(1):108; doi: 10.3390/pharmaceutics13010108
50.
SanchezI, MartinR, UssaF, et al.The parameters of the porcine eyeball. Graefes Arch Clin Exp Ophthalmol, 2011; 249(4):475–482; doi: 10.1007/s00417-011-1617-9
51.
Ruiz-EderraJ, GarcíaM, HernándezM, et al.The pig eye as a novel model of glaucoma. Exp Eye Res, 2005; 81(5):561–569; doi: 10.1016/j.exer.2005.03.014
52.
WagnerJA, EdwardsA, SchumanJS. Characterization of uveoscleral outflow in enucleated porcine eyes perfused under constant pressure. Invest Opthalmol Vis Sci, 2004; 45(9):3203; doi: 10.1167/iovs.03-1176
53.
BertschingerDR, BeknazarE, SimonuttiM, et al.A review of in vivo animal studies in retinal prosthesis research. Graefes Arch Clin Exp Ophthalmol, 2008; 246(11):1505–1517; doi: 10.1007/s00417-008-0891-7
54.
MatsuuraK, MiyoshiT, SutoC, et al.Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg, 2013; 39(11):1702–1706; doi: 10.1016/j.jcrs.2013.05.036
55.
Braga-MeleR, ChangDF, HendersonBA, et al.Intracameral antibiotics: Safety, efficacy, and preparation. J Cataract Refract Surg, 2014; 40(12):2134–2142; doi: 10.1016/j.jcrs.2014.10.010
56.
PackerM, ChangDF, DeweySH, et al.Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitis. J Cataract Refract Surg, 2011; 37(9):1699–1714; doi: 10.1016/j.jcrs.2011.06.018
57.
WolfA, Von JagowB, UlbigM, et al.Intracameral injection of bevacizumab for the treatment of neovascular glaucoma. Ophthalmologica, 2011; 226(2):51–56; doi: 10.1159/000327364
58.
ShahTJ, ConwayMD, PeymanGA. Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: Design, development, and place in therapy. Clin Ophthalmol, 2018; 12:2223–2235; doi: 10.2147/opth.s165722
59.
KinoshitaS, KoizumiN, UenoM, et al.Injection of cultured cells with a ROCK inhibitor for bullous keratopathy. N Engl J Med, 2018; 378(11):995–1003; doi: 10.1056/nejmoa1712770
60.
BandeMF, MansillaR, PataMP, et al.Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis. Sci Rep, 2017; 7(1); doi: 10.1038/s41598-017-18412-9
61.
De ClercqE.Antiviral drugs in current clinical use. J Clin Virol, 2004; 30(2):115–133; doi: 10.1016/j.jcv.2004.02.009
62.
SaraoV, VerittiD, BosciaF, et al.Intravitreal steroids for the treatment of retinal diseases. Sci World J, 2014; 2014:1–14; doi: 10.1155/2014/989501
63.
AndersonWJ, Da CruzNFS, LimaLH, et al.Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: A narrative review. Int J Retina Vitreous, 2021; 7(1); doi: 10.1186/s40942-021-00307-7
64.
SchargusM, FringsA. Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol, 2020; 14:897–904; doi: 10.2147/opth.s207978
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
